Early trial tests Triple-Threat drug combo for tough kidney cancers
NCT ID NCT05030506
Summary
This early-stage study is testing the safety and initial effects of a new drug, belzutifan, given alone and in combination with other cancer drugs (lenvatinib and pembrolizumab) for people in China with advanced kidney cancer. It will enroll 45 participants to see how their bodies handle the drugs and to check for early signs that the treatments might help control the cancer. The main goal is to find safe dose levels and understand side effects before larger studies can begin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer hospital-Digestive Oncology ( Site 0001)
Beijing, Beijing Municipality, 100142, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S
Nanjing, Jiangsu, 210000, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery Department ( Site 0005)
Guangzhou, Guangdong, 510060, China
-
The Second Affiliated hospital of Zhejiang University school of medicine-Urology ( Site 0007)
Hangzhou, Zhejiang, 310052, China
-
Tianjin Medical University Cancer Institute and Hospital ( Site 0003)
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.